Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 78

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 78
---
), currently in early-stage development, which represents a novel approach to immunization through innovative nanoparticle-based 
 vaccines. The delay in the pre-clinical animal (mice) study currently being conducted by Prof Barenholz of the Hebrew University                 
 in Jerusalem, which was to have been completed in the first quarter of 2025, has prevented management from receiving important additional        
 information respecting commercial viability (and additional potential IP protection) that could be available for the vaccine project.            |

The diagram below illustrates our product
pipeline across various stages of development.

However, even if
preclinical studies show promising results, there is no guarantee that such pharmaceutical candidate will demonstrate sufficient efficacy
in human populations.

<div align='center'>46

Our leading Product Candidate --Nano-Mupirocin</div>

Nano-Mupirocin is a novel NLP-based formulation
of a potent antibiotic mupirocin. Mupirocin is an antibiotic with a unique mode of action, not shared by any other therapeutically available
antibiotic. However, due to its rapid metabolic degradation following systemic administration and extensive plasma protein binding, the
therapeutic use of this well-established agent has been limited to topical application. The novel formulation of Nano-Mupirocin is specifically
designed to overcome the challenge of rapid metabolic degradation, enabling the development of a potent systemic therapy for life-threatening
antibiotic-resistant infections.

Antibiotic resistance occurs when bacteria
change in a way that makes antibiotics less effective or ineffective against them. This makes infections harder to treat and increases
the risk of disease spread, severe illness, disability, and death. Antibiotic resistance is driven by the misuse and overuse of antibiotics
in humans, animals, and plants, and is exacerbated by poverty and inequality.

Global Research on Antimicrobial Resistance
(GRAM) Project conducted and published by Cambridge University in 2024 demonstrated that globally antibiotic-resistant infections were
directly responsible for 1.45 million deaths and contributed to 5.35 million deaths in 2022. In the US alone, antimicrobial resistance
was responsible for 47,000 deaths and contributed to 180,000 deaths in 2022. [1]. These numbers are echoed by the 2022 report published
by WHO. Health management organizations and medical professionals around the world increasingly recognize antimicrobial resistance (AMR)
as one of the most urgent and escalating threats to global health and sustainable development.

We believe that our novel liposomal Nano-Mupirocin
may